• Categories:News
• Author:
• Origin:
• Time of issue:2021-02-05 15:19
• Views:

(Summary description) The U.S. Food and Drug Administration approved on the 2nd a treatment for type II diabetes oral tablet Tradjenta (generic name "Liragliptin") on the market, Liragliptin can be used to improve the ability of type II diabetes patients to control blood sugar.   Type II diabetes, also known as adult-onset diabetes, is the most common form of diabetes and is characterized by insulin resistance, meaning that the body is able to produce insulin, but the body's tissues are insensitive to the effects of insulin and normal amounts of insulin do not have a normal hypoglycemic effect. By inhibiting dipeptidyl peptidase-4, liragliptin raises the level of a hormone that stimulates insulin release, which in turn improves blood sugar control in those who take it.   The FDA said the drug's safety and effectiveness were demonstrated in eight double-blind clinical trials involving about 3,800 patients with type II diabetes, with major side effects including upper respiratory infections, runny nose, sore throat, muscle pain and headache.   Produced by Boehringer Ingelheim Pharmaceuticals in Connecticut, USA, Liragliptin can be taken alone or in combination with other available medications.